Phagenesis
Developms a device to treat dysphagia;a condition that disables the safe swallowing of food
Phagenesis has raised €64M across 4 funding rounds from 5 investors, most recently a Series D+ round in Mar 2024. Based in Manchester Science Park Pencroft, UK; founded 2007; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€64M
€63,803,954
Funding rounds
4
Investors
5
distinct backers
Active since
2010-09
latest 2024-03
Funding by year
EUR raised per yearPhagenesis — funding by year — interactive chart.
Data table
| Phagenesis — funding by year | |
|---|---|
| 2010 | €2.8M |
| 2011 | €7.0M |
| 2013 | €15M |
| 2024 | €39M |
Signals
High confidenceRaise-next likelihood11
base rate 53% for Series D+
- ▼ Past typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood8
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▲ 4 rounds raised
- ▼ Old (19y) — past typical exit age
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
4 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-03-04 | Series D+ | €39M | Aphelion,British Patient Capital,EQT Life Sciences,Northern Gritstone,Sectoral | View deal → |
| 2013-05-01 | Series B | €15M | — | View deal → |
| 2011-10-01 | Other | €7.0M | — | View deal → |
| 2010-09-01 | Other | €2.8M | — | View deal → |